- Home
- RLYB vs ICMB Comparison
RLYB vs ICMB Comparison
Compare RLYB & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- ICMB
- Stock Information
- Founded
- RLYB 2018
- ICMB 2012
- Country
- RLYB United States
- ICMB United States
- Employees
- RLYB N/A
- ICMB N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- ICMB Finance: Consumer Services
- Sector
- RLYB Health Care
- ICMB Finance
- Exchange
- RLYB Nasdaq
- ICMB Nasdaq
- Market Cap
- RLYB 42.7M
- ICMB 44.8M
- IPO Year
- RLYB 2021
- ICMB N/A
- Fundamental
- Price
- RLYB $0.75
- ICMB $3.18
- Analyst Decision
- RLYB Buy
- ICMB
- Analyst Count
- RLYB 5
- ICMB 0
- Target Price
- RLYB $9.75
- ICMB N/A
- AVG Volume (30 Days)
- RLYB 70.1K
- ICMB 28.1K
- Earning Date
- RLYB 03-11-2025
- ICMB 03-04-2025
- Dividend Yield
- RLYB N/A
- ICMB 15.09%
- EPS Growth
- RLYB N/A
- ICMB N/A
- EPS
- RLYB N/A
- ICMB 0.29
- Revenue
- RLYB $598,000.00
- ICMB $24,827,371.00
- Revenue This Year
- RLYB N/A
- ICMB N/A
- Revenue Next Year
- RLYB N/A
- ICMB N/A
- P/E Ratio
- RLYB N/A
- ICMB $10.91
- Revenue Growth
- RLYB N/A
- ICMB N/A
- 52 Week Low
- RLYB $0.73
- ICMB $2.91
- 52 Week High
- RLYB $3.46
- ICMB $3.67
- Technical
- Relative Strength Index (RSI)
- RLYB 37.62
- ICMB 66.63
- Support Level
- RLYB $0.73
- ICMB $3.10
- Resistance Level
- RLYB $0.84
- ICMB $3.23
- Average True Range (ATR)
- RLYB 0.07
- ICMB 0.06
- MACD
- RLYB -0.00
- ICMB 0.01
- Stochastic Oscillator
- RLYB 12.89
- ICMB 76.19
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.